This study demonstrates that rTMS promotes Aβ clearance and cognitive recovery in AD by activating GABAergic neurons and enhancing Cx3cl1‐Cx3cr1 signalling, providing a novel molecular target for non‐invasive AD therapy. Here, CX3CR1 is linked to Alzheimer disease.